Navigation Links
ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
Date:12/21/2007

Stability Testing Meets Specifications

Results Support Expiration Date Extension

TUCSON, Ariz., Dec. 21 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that it has submitted a lot release request to the Food and Drug Administration (FDA) with extended expiration dating on its inventory of urokinase drug product. Urokinase, ImaRx's first commercially available FDA-approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism.

The extended expiration dating was based on recent data from the Company's ongoing stability testing program that successfully met all of the required specifications necessary to support extension of the expiration dating of urokinase to between July and September of 2009. This extension would impact all of ImaRx's unlabeled vials of urokinase, which accounted for approximately 71% of the Company's inventory as of September 30, 2007. Based on successful completion of the stability testing ImaRx has submitted a request to the FDA to release one lot of urokinase drug product for commercialization.

"We are pleased to have submitted this lot release with extended expiration dating to the FDA," said Bradford A. Zakes, President and CEO of ImaRx. "Sales of urokinase have enabled the company to offset expenses associated with our clinical-stage development program for ischemic stroke with the revenue generated through product sales. FDA acceptance of our lot release will allow the company to unlock additional value from this asset and continue to commercialize this product."

ImaRx intends to continue its stability program to evaluate the potential for further expiration extensions beyond September 2009 for unlabeled vials of urokinase inventory.

ImaRx began selling urokinase in October 2006. The Company acquired the product and all related assets, including an approximate four-year supply of inventory, from Abbott Laboratories (NYSE: ABT) in April 2006 for a total purchase price of $20 million. As of September 30, 2007 the Company has received aggregate net proceeds of approximately $14.4 million from sales of urokinase to its wholesalers and customers.

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. ImaRx Therapeutics' commercialization efforts are currently focused on its product, urokinase for the treatment of acute massive pulmonary embolism.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include those related to our expectation that the FDA acceptance of our lot release will allow the company to unlock additional value from this asset and continue the commercialization of this product and any inference that our submission requesting the FDA to release one lot of urokinase drug product for commercialization will be allowed by the FDA. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include: sales of urokinase may decline and there may be insufficient demand for the product and the FDA may not approve our request for lot release which would result in insufficient supply of product thereby reducing sales of urokinase, and, we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of December 21, 2007, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

ImaRx Therapeutics, Inc. The Ruth Group

Jennifer Marshall Sara Ephraim (investors)

VP Corporate Dev. & Investor Relations sephraim@theruthgroup.com

jlmarshall@imarx.com Jason Rando (media)

(520) 770-1259 jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services ... of Eastern Michigan last Friday in order to aid in the Flint water crisis. ... include a facility located in Clio, only 15 miles away from Flint. , “We ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... ... 2016 , ... 10 Best Water is excited to announce a ... owners that topped the list as a result of their commitment to offering clients ... was Tibet 5100, a top notch water company that specializes in providing the public ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Fotona, based in the U.S. and Europe ... PRO Lightwalker dental laser at the upcoming 151 st ... 2016 in booth #4815. The ST PRO is a full ... the features of the award winning, industry leading Lightwalker ATS. At ... will be very attractive to many dentists hesitating to incorporate ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
Breaking Medicine Technology: